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Abstract
Adenomyosis seems to be the most widespread coexistent pathology included under the umbrella of common 
benign disorders of the human uterus. The incidence of adenomyosis is under discussion since different imag-
ing criteria are used. In the majority of cases, prevalence is determined among women with uterine fibroids 
and endometriosis or severe gynecological symptoms. This common benign pathology is asymptomatic in 1/3 
of cases. Up to 50% of women with infertility are affected by adenomyosis. It seems to be an important risk 
factor for spontaneous pre-term delivery and pre-term premature rupture of the membranes. Nowadays, 
the etiology of adenomyosis is still unclear and requires deeper investigation. This review summarizes the 
aspects of prevalence, co-existence, risk factors, classification, mechanisms of pathogenesis, genes and im-
munological features, main histological features, animal models, and clinical manifestation of adenomyosis. 
It might facilitate understanding of the independent nature of such a dual enigma as adenomyosis.
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Introduction
Adenomyosis is a benign condition of the uterus char-
acterized by the presence of ectopic endometrial glands 
and stroma below the endometrial-myometrial junction 
(at a depth of at least 2.5 mm below the basal layer of the 
endometrium).1,2 The focuses of endometrial glands and 
stroma in the myometrium are typically surrounded by its 
hyperplastic tissue.3 Lymphatic and vascular channels car-
ry out penetration of normal myometrium.4,5 The level 
of endometrial invasion into a myometrium has been the 
issue of heated debate.6 The majority of cases are observed 
in multiparous premenopausal women. Likelihood estima-
tion of diagnosis demands obligatory histological analyses, 
which are commonly provided after hysterectomy. By far, 
the majority of adenomyosis cases are detected in autopsy 
and coexist with endometriosis and uterine fibroids, which 
explain a wide range of distribution (from 5% to 70%) ac-
cording to literature data.4,7
Historical notes
A Bohemian physician and pathologist, Carl von Roki-
tansky, first described adenomyoma as a focal core of en-
dometrial glands and stroma surrounded by  smooth 
muscle cells in 1860. He referred to it as “cystosarcoma 
adenoids uterinum” with a neoplastic nature.8–12 Surpris-
ingly, Knapp, an expert in the history of medicine, in 1999 
claimed that the 1st who described a similar condition (lat-
er named adeno- or endometriosis) was Daniel Schrön 
from Germany in 1690 in the work “Disputatio Inauguralis 
Medica de Ulceribus Uteri”. Moreover, some of pathologi-
cal descriptions made between the 17th and 18th centuries 
are similar to the modern classification of endometriosis 
or adenomyosis. Knapp challenged the primacy in describ-
ing the pathology in his Letter to Editor of Fertility and 
Sterility, which was published. Unfortunately, his request 
remained unanswered due to the author's sudden death 
within a few months after publication.12
The name adenomyoma was coined around the end 
of the 19th century. In 1896, both Cullen and Von Reck-
linghausen described the condition, followed by Pick and 
Rolly in 1897.11 In addition, Cullen provided the 1st ever 
classification of  adenomyomas, while its pathogenetic 
nature was depicted by Meyer in 1903. He emphasized 
that it is a variant of “epithelial invasion of inflammatory 
infiltrated tissue” and affects 2 kinds of epithelium: dys-
topic and orthotopic (embryonic and mature). The origin 
of dystopic nature was also supported by Orloff, who de-
scribed it in 1895 as “glandular spaces under the serosa 
covering uterine myomata”, and focused on developing 
from “embryonic cells”.10–12
Until the 1920s, adenomyosis and endometriosis were 
considered to be a part of the same entity.13 In 1925, Frankl 
depicted and named the invasion of mucosal tissue in the 
myometrium as “adenomyosis uteri”, thereby singling out 
adenomyosis among adenomyomas.10–12
Finally, in 1972, Bird proposed the modern explanation 
of adenomyosis. He described that adenomyosis is a non-
malignant endometrial invasion into the myometrium and 
leads to macroscopic changes of uterus size. Under a mi-
croscope, hypertrophy and hyperplasia of the myometrium 
are observed with penetration of the endometrium inside 
(glands and stroma). Nowadays, this gynecological disease 
is characterized by the invasion of endometrial compo-
nents more than 2.5 mm below the endo-myometrial junc-
tion in the microscope’s low-power field.2,9,12
Prevalence and co-existence 
of adenomyosis
The incidence of adenomyosis is unclear and debatable 
due to the use of a variety of criteria.12 Numerous publi-
cations have shown that the prevalence of adenomyosis 
widely varies (from 5–8% to 40–70% of all uterine speci-
mens), with a mean of 20–25%.4,7,8 The same statistical 
data was present after histological analysis of postoperative 
material. Based on a literature review, prevalence of adeno-
myosis ranges from a high of 61.5% to a low of 8.8%, with 
a peak among women between 35 and 50 years of age.7,14
The diagnosis of adenomyosis can be time-consuming 
and challenging, based on lucky histological observation 
of the material. Interestingly, the rate of detection depends 
on the quantity and quality of samples observed and can 
vary from 31% to 62 % in the same uterus.9
Current studies demonstrate that about 4/5 of  cases 
with adenomyosis coexist with uterine fibroids and endo-
metriosis.5,15 According to statistical data, approx. every 
5th removed uterus with leiomyomata has a focus of adeno-
myosis, while up to 55% of adenomyosis samples reveal devel-
oping uterine fibroids. Kitawaki proved these conclusions 
with his own analysis of data presented of the coexistence 
of both pathologies: adenomyosis with leiomyomata in 
35–55% of cases, while leiomyomata with adenomyosis 
in 64%. At the same time, Kitawaki noted that adenomyosis 
is associated with endometriosis too: adenomyosis with 
endometriosis in 70% of cases, while “vice versa” only in 
6–20% of all cases.7
It is important to note that diseases such as polyps of the 
endometrium, typical and atypical endometrial hyper-
plasia and endometrial carcinoma often coexist with ad-
enomyosis, compared to their separate detection.7 On the 
other hand, no study has demonstrated the natural trans-
formation of adenomyosis to adenocarcinoma.16
Risk factors
It is important to consider that adenomyosis often co-
exists with other gynecological disorders and is revealed 
by  histological examination. As it  appears from these 
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features, suggested risk factors could not be clearly evalu-
ated and most of them were received after retrospective 
studies.
Adenomyosis is common for women in the 5th decade 
of life but it has also been revealed in patients in the post-
menopausal period after chemotherapy of breast cancer 
with tamoxifen.9,17 Increasing age up to menopause has 
long been considered a risk factor.18
Multiparity is associated with adenomyosis. This might 
be explained by a mechanism of trophoblast invasion into 
the myometrium during pregnancy.9,19 Romanek et  al. 
proved by analysis that the relative risk of adenomyosis 
was almost 2  times lower among nulliparous women 
in  comparison with multiparous.19,20 Different studies 
have presented controversial data regarding abdominal 
delivery and further risk of pathology development; the 
role of cesarean sections also remains unclear.19
Undoubtedly, sex hormones have a great impact on adeno-
myosis.21 It has been demonstrated that estrogen receptors 
are always present in adenomyosis tissue, however, their 
quantity was reduced compared to a corresponding normal 
myometrium.7 Progesterone and androgen receptors were 
also found in adenomyotic tissue. Some authors have noted 
a balance between the amount of both steroids in healthy 
and adenomyotic tissue, while others have demonstrated 
a slightly higher density of progesterone receptors when 
compared to estrogen. It is important to note that ectopic 
as well as eutopic endometrium reflect all cyclic changes.22
Several studies have revealed that smoking can also be 
a risk factor of adenomyosis. Shrestha showed that the risk 
of adenomyosis is higher in smokers, especially in those 
who smoked for more than 10 years.20 On the other hand, 
Taran et al. noted that smokers appear less likely to have 
adenomyosis and this might be explained by declining es-
trogen levels in the blood, which is common for smokers.7,9
Panganamamula et al. focused attention on previous 
surgery on endometrium, proved the first hypothesis 
that endometrial resection’s involvement in pathogenesis 
of adenomysosis, made by Coltate and Smith in 1991.23 
The data rendering a strict direct link between adenomyo-
sis and uterine trauma is still inconsistent. As often as not, 
in the literature, such traumatic conditions as spontaneous 
abortion, dilation, curettage, and endometrial ablation are 
discussed.23 Levgur et al. noticed that the instrumental 
curettage of the uterus could be a risk factor only in the 
case of abortion, whereas in the nonpregnant uterus it did 
not impact subsequent development of adenomyosis.4,23,24 
If it is not expelled, a pregnancy could be a crucial point 
in the expansion of adenomyosis. One argument in favor 
of this is the fact that, despite about 20% of nulliparous 
women presenting with adenomyosis, a higher percent-
age of women after any term of pregnancy are affected 
by the disease.7
Some studies have shown that production of prolactin 
by the endometrium, myometrium and even in leiomyomas 
could stimulate a mitogenic activity in smooth muscle cells 
through its receptors. This may suggest a link between 
adenomyosis and depression with a common pathogenic 
factor.9
Classification
Adenomyosis has 2 types: diffuse and focal, which is also 
named “adenomyoma” in the literature. In comparison 
with the anterior and lateral sides of the uterus, the pos-
terior wall is affected more often.6,12
Bird et al. in 1972 divided the depth of  invasion into 
3 grades. The 1st grade is characterized by the existence 
of adenomyosis within 1 low-power field below the basal 
endometrium. The  2nd grade is  represented by  deeper 
penetration, to the mid-myometrium, while the 3rd grade 
penetrates beyond the mid-myometrium. His team as-
sessed the extent (density) of glandular involvement of the 
myometrium as follows: “slight” – a few (1–3) adenomyotic 
glands per low-power field; “moderate” – several (4–9) and 
“marked” – many (10 or more).6
Definition of endomyometrial 
junctional zone
The endomyometrial junctional zone (JZ) is a distinct, 
hormonally sensitive part of the endomyometrial interface 
that was first visualized more than 20 years ago by magnetic 
resonance imaging (MRI).3,10 However, the realization that 
the inner portion of the human myometrium constitutes 
a separate entity within the uterine musculature is more 
than a century old. Brosens et al. referred to Werth and 
Grusdew, who called it the “archimyometrium” in 1898.25
The JZ is not the outer myometrium.12 They have different 
origins: the JZ originates from the Müllerian ductus and the 
outer myometrium from the mesenchyme. As endometrium, 
the JZ expresses steroid hormone receptors, has a cycle-de-
pendent type of growth and is involved in implantation and 
deep placentation. Also, normal uterine peristaltic activity 
originates from the JZ. This zone has been cited in literature 
as the archimyometrium, stratum basale, inner myometrium, 
junctional zone myometrium, endometrio–myometrial inter-
face, transitional zone, and sub-endometrial myometrium. 
Ultrasound and MRI detect this zone in human uteri. Com-
monly, the thickness of the JZ is 5 mm or less, whereas it has 
a tendency to grow with age. Physiologically, JZ could be up 
to 0.8 cm among women without adenomyosis and 1.1 cm 
among those affected, respectively.26,27
The changing of JZ size and characteristics (>12 mm, 
hemorrhagic high-signal myometrial spots) is a poor prog-
nostic for adenomyosis and has a strong correlation with 
prognosis.25,28 It has been called the gold standard in re-
vealing adenomyosis. Bergeron et al. hypothesized that 
a disturbance of JZ may be involved by triggering an “in-
vasive” factor.5
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Pathogenesis
The etiology of adenomyosis is still uncertain. Some 
theories equally explain the possible pathogenesis of the 
disorder while at the same time complementing each other. 
They focus on local invasion, cellular proliferation and 
angiogenesis.
This pathological condition originates from the deep 
basal layer of the endometrium as a result of its invagi-
nation in the myometrium, possibly due to loss of tissue 
cohesion. Tissue affected by adenomyosis is character-
ized by higher expression of estradiol receptors (ER) com-
pared to typical endometrium, combined with expression 
of the apoptosis-suppressing gene product – B cell lym-
phoma/leukemia-2 (Bcl-2) protein. Enhancement of Bcl-2 
expression is  involved in  the pathogenesis of  uterine 
adenomyosis.5,29–31
From another point of view, the basalis invaginates into 
the myometrium along the lymphatic vessels. This was 
proved by pathological examination of postsurgical sam-
ples – adenomyotic focuses were found within intra-myo-
metrial lymphatics. As the endometrial and myometrial 
tissues originate from the Müllerian ducts, adenomyosis 
can be the result of metaplasia from de novo ectopic intra-
myometrial endometrial tissue. This was defined as the 3rd 
theory of the pathogenesis of adenomyosis.5
It should be noted that myofibroblasts express some ex-
tracellular matrix proteins and definitely take part in the 
development of pathological focuses. The invasion of endo-
metrial tissue inside the myometrium leads to its hypertro-
phy as a consequent response.28 Mast cells in the endome-
trial tissue are located in close vicinity to smooth muscle 
cells and impact its differentiation and development by se-
creting nerve growth factor (NGF), preadipocyte factor-1 
(Pref-1) and insulin-like growth factor-2. It is important 
to note that NGF is involved in the mechanism of pain 
and might reflect the severity of the process, which can be 
useful from the clinical point of view. Preadipocyte factor-1 
could be a possible protective factor for further differen-
tiation of cells. Koike et al. concluded that the mast cell 
might preserve the balance in an affected uterus.28 Zhao 
et al. observed the expression levels of caveolin 1 (CAV1) 
in adenomyosis-affected tissue and showed that focuses 
of adenomyosis have a low level of CAV1 expression, which 
could be associated with adenomyosis-related dysmenor-
rhea.32 The latest data provided by An et al. depicted that 
macrophages have an impact on epithelial–mesenchymal 
transition (EMT)-like processes, and thereby could be ef-
fector cells in that disease.33
Currently, the interest of researchers is focused on ab-
normal angiogenesis in JZ, which might be involved in the 
pathogenesis of adenomyosis. Moreover, abnormal vas-
cularization is common for half of the patients: vascular 
distribution is generally irregular and vessels are thick, 
dilated, and/or reticular.13 Vascular endothelial growth 
factor (VEGF), fibroblast growth factor (FGF)-1, FGF-2, 
thrombospondin 1 (TSP-1), and platelet-derived growth 
factor (PDGF) are potent angiogenic factors.28
In  general, adenomyosis is  characterized by  overex-
pression of VEGF and hypoxia-inducible factor 1-alpha 
(HIF1-alpha), increasing the number of  small vessels. 
Kang et al. observed 2 alleles of VEGF genes (22578A and 
21154A) and concluded that they might be protective fac-
tors of adenomyosis.13,34 Tokyol et al. emphasized that the 
quantity and intensity of cyclo-oxygenase (COX-2) expres-
sion in the endometrium was growing during both phases 
of the cycle in patients with adenomyosis in comparison 
to healthy controls.35 Another characteristic feature of the 
pathology is the prevalence of defective myometrial spiral 
artery remodeling associated with alteration.36
In  adenomyosis-induced animal models, the insulin 
growth factor-II (IGF-II) mRNA was found to be mark-
edly downregulated compared to normal endometrium, as 
observed by a global gene transcription profiling analysis. 
Levy et al. proved this with the same tendency of IGF-II 
expression.21 Despite that, its expression in uterine fibroid 
has the opposite character and this likely indicates dif-
ferent molecular and pathogenic backgrounds of uterine 
fibroid and adenomyosis. However, the expression of IGF-II 
can stimulate abnormal myometrial growth in patients 
with adenomyosis, explaining the frequent coexistence 
of both pathologies.
Histological features
Adenomyosis is identified in 20–30% of all uteri removed 
at surgery, where it causes globular and cystic enlargement 
of the myometrium, with some cysts filled with extrava-
sated, often hemolyzed red blood cells and siderophages.5 
However, in specimens larger than 280 g it is much less 
common.4 Microscopically, populations of spindle cells in-
clude smooth muscle cells and components of adenomyotic 
lesions, and make contact with the adenomyotic stroma.28 
On gross examination, the myometrium contains small, 
soft, red areas, some of which are cystic. Microscopic ex-
amination of these lesions reveals glands lined by mildly 
proliferative to  inactive endometrium and surrounded 
by endometrial stroma. Secretory changes are rare, except 
during pregnancy and in patients treated with progestins. 
Myometrial changing (hyperplasia and hypertrophy) could 
lead to enlarging of the uterus.19 Over time, the uterus 
may also be enlarged from cyclic bleeding into adenomy-
otic foci. Varying degrees of glandular hyperplasia may be 
seen, and occasionally hyperplastic surface endometrium 
extends into the foci of adenomyosis.37
Pathological foci are usually seen at a depth of at least 
2 mm in the myometrium on more than 1 microscopic field 
at ×10 magnification of the JZ. This is useful and impor-
tant for the uterus during pregnancy and postmenopause. 
Glands and stroma in  adenomyosis are usually in  the 
proliferative phase, whereas they may contain secretory 
to menstrual transformations. The stromal fibroblasts are 
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histologically different from myocytes.5 During differential 
histological analysis, it is important to pay attention to the 
features of adenomyoma (different from adenomyosis): 
usually circumscribed, nodular aggregate of smooth mus-
cle, endometrial glands and (usually) endometrial stroma.5
Genes and immunity 
of adenomyosis
Genetic factors can explain the nature of  a  variety 
of diseases, and adenomyosis is no exception. Wang et al. 
has not revealed any chromosomal aberrations during 
examination of 25 cases of adenomyosis by comparative 
genomic hybridization.7 Mutations in k-ras and p53 are 
common in adenomyosis.5 Kitawaki has mentioned that 
Goumenou et al. observed 31 cases of adenomyosis and 
revealed the incidence of loss of heterozygosity on 2p22.3-
p16.1, 3p24.2-p22 and 9p21 chromosomal regions as 19.4%, 
9.7% and 6.5%, respectively.7 Human leukocyte antigen-DR 
(HLA-DR) expression is significantly higher in stromal 
cells compared to glandular cells in adenomyosis tissue. 
This might be involved in the immune reactions which 
occur in adenomyosis.38
Goumenou et al. observed the expression of p16, retino-
blastoma (pRb) and cyclin D1 oncoproteins in patients with 
adenomyosis. Loss of expression of either pRb or p16, or the 
overexpression of cyclin D1, could lead to tissue growth. 
His team showed that for endometrial tissue in patients 
with adenomyosis during the 1st phase of the cycle, high 
expression of p16 was and low of pRb is common, whereas 
for endometrioma this balance was reversed. He concluded 
that the prevalence of p16 expression was common for 
adenomyosis in comparison with endometriomas. This 
clarified the differences in pathogenic mechanisms during 
both widespread gynecological pathologies.39
Fibroblast growth factor 2 (FBG2) is located on chromo-
some 4q26–27. It can upregulate the expression of VEGF 
and synergistically act with VEGF in stimulating new vessel 
formation. Kang et al. demonstrated that the FGF2 754C/G 
polymorphism is correlated with increased risk of adeno-
myosis among Chinese women.28,34,40
For identification of endometrial stromal cells among the 
myometrium in adenomyotic foci, immunohistochemical 
staining for CD10 is used, while it cannot distinguish such 
pathological conditions as myometrial invasion and carcinoma 
of endometrium from those involving adenomyosis (in situ). 
The cells close to the neoplasm also express this marker.5
Vimentin expression is lower in adenomyosis in com-
parison with eutopic endometrium, while expression 
of α-smooth muscle actin and desmin is consistent.28
Interleukin-10 (IL-10) is an important immunomodula-
tory cytokine produced by many cell populations. It is one 
of the major anti-inflammatory cytokines and plays im-
portant role in  several chronic inflammatory diseases 
and cancers. Wang et al. demonstrated that patients with 
adenomyosis have elevated expression of IL-10 in eutopic 
and ectopic endometrium (in the secretory phase), which 
could play a significant role in the pathogenesis of this dis-
ease by altering the immune system.41 Later, Qin et al. ob-
served the expression of interleukin-10 receptor 1 (IL-10R1) 
and interleukin-10 receptor 2 (IL-10R2) in adenomyosis. 
They showed that expression of IL-10R1 and IL-10R2 was 
higher in adenomyotic samples in comparison with eutopic 
endometrium of women with adenomyosis or in normal 
endometrium. They suggested that IL-10 receptors have 
a possible connection to the immunotolerance and/or anti-
inflammatory process during adenomyosis.42
Leukemia inhibitory factor (LIF) is a pleiotropic cytokine 
of the interleukin-6 family, produced by the endometrium 
during the implantation window. Xiao et al. found signifi-
cantly lower LIF immunolabeling intensity in women with 
adenomyosis in comparison to fertile women. The dys-
regulation of both LIF mRNA and protein in the endo-
metrium during the implantation window suggests that 
adenomyosis may be associated with impaired implanta-
tion.43,44 Garavaglia et al. noted an overxpression of the hu-
man leukocyte antigens (HLA) of class II and an increase 
of complement components C3 or C4 in adenomyosis.13,31
Model systems
Nowadays, different animal models are widely used for 
the observation and re-creation of adenomyosis, while for 
endometriosis only humans and non-human primates are 
used.45 Usually, as the object of experimental models for 
adenomyosis, non-human primates, horses, dogs, cats, rab-
bits, and laboratory rodents are used.28 This pathology 
occurs naturally in non-human primates, notably Macaca 
mulata. Several mouse strains also develop adenomyosis 
spontaneously and it can be found in a small percentage 
of adult animals.17,46 Moreover, spontaneous development 
of adenomyosis with a prevalence of ~80% by 12 months 
of age was revealed in CD-1 mice.42 Adenomyosis has also 
been induced in mice by hormonal manipulation such as 
by the implantation of a single anterior pituitary gland 
into the uterine lumen.17 Other experiments were focused 
on the administration of tamoxifen and further develop-
ment of adenomyosis in mice. Far fewer studies on ad-
enomyosis have been performed in rats than in mice. 
Rabbit is a convenient animal model because pathology 
can spontaneously manifest and its prevalence can be 
enhanced by estrogen administration during a period 
of 1–2 years.45
Symptoms
Adenomyosis does not present pathognomonic clinical 
symptoms.6,13 About 1/3 of women with adenomyosis do 
not have any symptoms.4,5,12 The most frequent symptoms 
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are common with other gynecological disorders: men-
orrhagia, dysmenorrhea, metrorrhagia, dyspareunia, 
and chronic, erratic or constant pelvic pain. Symptoms 
of heavy/abnormal bleeding are thought to be positively 
associated with the depth of penetration of adenomyosis 
into the myometrium.25,47–49 Dysmenorrhea is correlated 
with the prevalence of adenomyotic glands.6
Diagnosis
In general, symptomatology does not allow detection 
of adenomyosis in time. The diagnosis can include vaginal 
examination, transvaginal sonography (TVS) and MRI.18 
Unfortunately, diagnostic hysteroscopy does not make 
it possible to discover pathognomonic signs in such cas-
es.12 On pelvic examination, the uterus may be enlarged, 
soft and mildly tender, especially if a patient is examined 
premenstrually. Ultrasonography is helpful to observe the 
size and shape of the uterus (a globular or asymmetrical 
uterus, myometrial cysts), localization of heterogeneous 
myometrium and of focal abnormal echotexture.  Three-
dimensional reconstruction of the uterine anatomy in the 
coronal plane provides new and unrivaled views of the JZ.3 
Sometimes, the adenomyosis may be confined to a part 
of the myometrium in the form of a well-circumscribed 
lump, which is called adenomyoma. This is  in contrast 
to the uterine myoma, which does not present a well-de-
fined capsule.15
Although pelvic ultrasound is a widely accepted imaging 
modality, the reported sensitivity for the trans-abdominal 
approach is only 32–63% with a corresponding specificity 
of 95–97%.50 Improvement may be achieved with a trans-
vaginal approach. Hysterosalpingography may be of help, 
while diverticula extending into the myometrium are 
present. Magnetic resonance imaging allows observation 
of the inner myometrium and detection of its thickness 
and nature of changes, which is considered the hallmark 
of adenomyosis.12
Undoubtedly, the histological examination of  a  few 
postsurgical uterine transmural sections (from body and 
fundus) provide the final diagnosis.5 Only histological 
examination can reveal the existence of ectopic glands 
in the endometrium (the “adeno” component), different 
from those received by  different imaging techniques, 
which in the majority observe the organization of smooth 
muscle (the “myosis” component).10
Treatment
The  primary indication for treatment is  the pres-
ence of symptoms that negatively affect woman’s daily 
life. Conservative treatment of pain with nonsteroidal 
Fig. 1. Transvaginal ultrasound B-mode scan. Sagittal view. Typical 
changes within the uterus for adenomyosis: enlarged vascular spaces 
within the inner layer of myometrium and small myometrial cysts (sub-
endometrial cysts – specific sign)
Fig. 2. Transvaginal ultrasound color Doppler scan. Sagittal view. 
Increased vascularity within myometrium is demonstrated, which is one 
of the ultrasound adenomyosis features
Fig. 3. Transvaginal ultrasound B-mode scan (amber filter). Sagittal view. 
Typical for adenomyosis changes within the uterus: sub-endometrial 
echogenic linear striations and acoustic shadowing as a result 
of ultrasound beam diffraction by irregular structure of myometrium 
– endometrial tissue causes a hyperplastic reaction (“Venetian blind” 
appearance)
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anti-inflammatory drugs (NSAIDs) and hormonal con-
trol of excessive cyclic bleeding maintain the first line 
of management. Oral progesterone, contraceptive pills, 
hormonal patches or rings, or levonorgestrel intrauterine 
device (IUD) can effectively control symptoms. When con-
servative management is not efficient or contraindicated, 
surgical manipulations (endometrial ablation/resection, 
myometrial excision/reduction, myometrial electrocoagu-
lation, uterine artery ligation) are used for the treatment 
of symptoms. However, these methods are not very effec-
tive.9 For superficial adenomyosis, using endoscopic endo-
metrial ablation is preferred.5,51 The coexistence of uterine 
fibroids and adenomyosis in 1 patient could complicate 
the diagnosis as the have a similarity in symptoms. Thus, 
in both pathologies uterine artery embolization (UAE) 
is performed.9 Less than a half of patients after such surgi-
cal treatment have regression in 2–3 years.19 Unfortunately, 
variants with leiomyomata are still complicated to identify 
among patients with adenomyosis. The former detailed 
diagnosis of both pathologies might be helpful before UAE, 
by reason of poor post-surgical prognosis among women 
with adenomyosis.14 If a woman is not a candidate for any 
medical or surgical conservative management or if that 
treatment cannot sufficiently control the symptoms, hys-
terectomy is the final line of treatment.
Outcome
The junctional zone is quite important for the process 
of human placentation and is characterized by unique 
vascular plasticity in terms of physiological remodeling 
of the myometrial spiral arteries in pregnancy. Increasing 
thickness of JZ, changes in neo-angiogenesis and altera-
tions in this zone, which are common for adenomyosis 
and endometriosis, may be associated with a shallow type 
of defective deep placentation.10–12 As it appears from this 
statement, both pathologies may form the pathogenic back-
ground for negative obstetric outcome (preterm birth, fe-
tal growth retardation and postpartum hemorrhage).36 
Several studies have proved that women with adenomyosis, 
revealed before pregnancy, had significantly increased risk 
of preterm delivery, preterm premature rupture of mem-
branes, fetal malpresentation and cesarean delivery. Hypo-
thetically, this could be connected with the enlargement 
of adenomyotic focuses during pregnancy and further its 
association with inflammatory consequences.52–54 Adeno-
myosis is connected with impaired implantation, destroy-
ing the uterine cavity’s receptivity, accompanied by  lower 
expression of the adhesion molecules necessary for embryo 
implantation (integrin β-3 and osteopontin). These factors 
make it possible to evaluate patients with adenomyosis as 
a target group for in vitro fertilization (IVF) treatment.39,55
Neoplastic transformation of adenomyosis is rare: only 
a few case reports of adenocarcinomas have been pub-
lished. Koike et al. analyzed all the available data and pre-
sented in their review, to date, 44 cases that have been 
documented.28
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